Phase I study of etirinotecan pegol [NKTR 102] in patients with refractory solid tumours

Trial Profile

Phase I study of etirinotecan pegol [NKTR 102] in patients with refractory solid tumours

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2008

At a glance

  • Drugs Etirinotecan pegol (Primary)
  • Indications Gastrointestinal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 24 Oct 2008 Positive interim results were presented at the 20th EORTC -NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics', according to a Nektar media release.
    • 24 Oct 2008 In a media release, Nektar announced that the company expects to present complete results at additional scientific forums later this year.
    • 02 Jun 2008 Results have been presented at ASCO 2008; complete results are expected later in 2008, according to a Nektar Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top